Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ... 7 February 2025 – Novo Nordisk today announced interim results ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...

WASHINGTON (dpa-AFX) - Novo Nordisk A/S (NVO) announced that data from the phase 3 FRONTIER2 trial demonstrated the superiority of Mim8 prophylaxis over both on-demand treatment and prior clotting ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in patients aged one to 11 years. The phase 3 FRONTIER3 trial initially evaluated a ...

Novo Nordisk's stock has dropped to $110 per share ... Phase 3 trials are ongoing, with results expected between 2026 and 2027. Mim8: This is a phase 3 medication for the treatment of hemophilia ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) has been ...